Trial Profile
Efficacy and safety trial of AJG533 with long term treatment in patients with chronic constipation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2020
Price :
$35
*
At a glance
- Drugs Elobixibat (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Sponsors Ajinomoto Pharma; Albireo AB; EA Pharma
- 09 Jul 2018 According to an Eisai Co Ltd media release, data from this trial has been published in The Lancet Gastroenterology & Hepatology, and was also presented at the Digestive Disease Week (DDW) 2018.
- 05 Jun 2018 Results determining the safety and efficacy of elobixibat for the treatment of chronic constipation from two trials (JapicCTI-153061 and JapicCTI-153062) presented at the Digestive Disease Week 2018
- 30 May 2017 Status changed from active, no longer recruiting to completed.